NASH: Current and future therapies | With Prof. Philip Newsome

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/71/0d/9f/710d9fb0-cc0e-a2e5-bb5d-e3172f7edad6/mza_17901817495047371423.jpg/600x600bb.jpg

Diabetes Knowledge into Practice Podcast

Liberum IME

23 episodes

1 week ago

A summary of new trial data, guideline recommendations and expert opinion across diabetes care, run by Diabetes Knowledge into Practice (https://diabetes.knowledgeintopractice.com), featuring interviews with leading experts from across the globe. This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.

Medicine

Health & Fitness

RSS

All content for Diabetes Knowledge into Practice Podcast is the property of Liberum IME and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo400/1944169/1944169-1633442889543-d945f63b05428.jpg

NASH: Current and future therapies | With Prof. Philip Newsome

Diabetes Knowledge into Practice Podcast

14 minutes 16 seconds

3 years ago

NASH: Current and future therapies | With Prof. Philip Newsome

This is a special episode brought to you in association with Hepatology Knowledge into Practice.

NASH has historically had very few treatment options, with none currently indicated specifically for NASH. But a large number of ongoing clinical trials means that treatment may look different in the future.

Join Professor Philip Newsome for an overview of current treatments in NASH, as well as how treatment may change in the future.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References:

References are available here

Disclosures:

Prof. Philip Newsome declares the following:

Consultant on behalf of the University of Birmingham: Boehringer Ingelheim, Novo Nordisk, Intercept, BMS, Gilead, Poxel Pharmaceuticals

Grants/Research Support recipient: Novo Nordisk, Boehringer Ingelheim

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.